Release Date: April 30, 2017
Expiration Date: April 30, 2018
Media: Internet - based
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma consists of a series of interactive clinical vignettes, short video interviews with leading experts in hematologic malignancies, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.
CME/CE Activity Table of Contents
- Module 1. Multiple Myeloma
- Module 2. Lymphoma
- Module 3. Chronic Lymphocytic Leukemia
- Module 4. Chimeric Antigen Receptor T Cells
Requirements for Successful Completion
You will need to login to participate in the activity. In order to receive a CME/CE certificate, participants must view any number of the modules, complete the posttest with a passing score of 70% or higher, complete the evaluation, and request credit. Participants may immediately download a CME/CE certificate upon completion of these steps.
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.
At the conclusion of this activity, participants should be better prepared to:
- Describe current and evolving genomic and molecular biomarkers that can be used to stratify risk and inform clinical decision making in the management of hematologic malignancies
- Assess landmark clinical trial results in the context of how they impact evolving clinical practice paradigms and can be applied to personalize care and optimize outcomes
- Delineate effective strategies to proactively mitigate and manage predictable side effects related to the management of hematologic malignancies so that treatment outcomes can be maximized
- Evaluate recent clinical trial findings concerning novel compounds or strategies to manage hematologic malignancies
- Consider the therapeutic implications of emerging data on evolving treatment paradigms for patients with hematologic tumors
Faculty, Staff, and Planners' Disclosures
Andre Goy, MD, MS
Chairman and Director, Chief of Lymphoma
Director, Clinical and Translational Cancer Research
John Theurer Cancer Center at Hackensack University
Hackensack Meridian Health
Professor of Medicine, Georgetown University
Disclosure: Grant/Research Support: Johnson & Johnson, Celgene; clinical trial support through institution; Consultant: Celgene; Speaker’s Bureau: Takeda, Johnson & Johnson/Pharmacyclics; Other: Member on advisory board: Celgene; Takeda; Pharmacyclics; Johnson & Johnson
Sagar Lonial, MD, FACP
Professor, Emory School of Medicine
Chair, Department of Hematology & Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Disclosure: Consultant: Merck, Novartis, Onyx, Millennium, Bristol-Myers Squibb, Sanofi, Celgene, Janssen Pharmaceuticals Companies
Jennifer R. Brown, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Director, CLL Center
Dana-Farber Cancer Institute
Disclosure: Consultant: Janssen Pharmaceuticals Companies, Gilead, Celgene, Sun BioPharma, Novartis, AbbVie, Pfizer, AstraZeneca, Astellas, RedX
Alfred L. Garfall, MD, MS
Assistant Professor of Medicine
Perelman School of Medicine, University of Pennsylvania
Division of Hematology Oncology
Disclosure: Grant/Research Support: Novartis, BioInvent
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.